Garner Thomas 4

What Happened
Garner Thomas, Executive Vice President and Chief Commercial Officer of ACADIA Pharmaceuticals (ACAD), was granted two awards on 2026-03-06: 97,947 shares as a stock option award (derivative) and 28,493 restricted stock units (RSUs). Both grants are reported as acquisition code "A" (award/grant) and show an acquisition price of $0, so the Form 4 reports $0 as the transaction value. These are grants (not open-market purchases or sales) and typically reflect compensation/retention awards rather than immediate market bets.

Key Details

• Transaction date: March 6, 2026; Filing date (Form 4): March 10, 2026 (filed within required two business days).
• Grants: 97,947 stock options (derivative) and 28,493 RSUs; aggregate units = 126,440. Reported acquisition price: $0.
• Vesting / footnotes:
  • F1 (options): 25% of the option shares vest and become exercisable on March 6, 2027; remaining shares vest in 36 equal monthly installments thereafter.
  • F2 (RSU definition): Each restricted stock unit represents a contingent right to receive one share of common stock.
  • F3 (RSU vesting): RSUs vest in four equal annual installments beginning March 6, 2027.
• Shares owned after transaction: Not specified in the provided filing.
• No sale, exercise, tax-withholding, or 10b5-1 plan indicated in this filing.

Context
These awards are typical executive compensation grants intended to retain and incentivize management; they do not involve an immediate purchase or sale of market shares. Options and RSUs vest over time per the schedules above — only vested option shares can be exercised and RSUs convert to shares on vesting. Because the filing reports grants (not sales), it should not be read as a short-term market sentiment signal.